New Insight on Human Type 1 Diabetes Biology: nPOD and nPOD-Transplantation

Current Diabetes Reports

Volumn 14, Issue 10, 2014, Pages

  Pugliese, Alberto ^a   Vendrame, Francesco ^a   Reijonen, Helena ^b   Atkinson, Mark A ^c   Campbell Thompson, Martha ^c   Burke, George W ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b BENAROYA RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

nPOD; Pancreas; Transplantation; Type 1 diabetes

Indexed keywords

CLINICAL TRIAL (TOPIC); HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MEDICAL LITERATURE; NONHUMAN; ORGAN DONOR; PANCREAS TRANSPLANTATION; REVIEW; AUTOIMMUNITY; BLOOD; COOPERATION; DONOR; HEALTH CARE FACILITY; IMMUNOLOGY; MEDICAL RESEARCH; ORGANIZATION AND MANAGEMENT; PANCREAS; PANCREAS ISLET BETA CELL; PATHOLOGY; PROCEDURES; SECRETION (PROCESS);

AUTOANTIBODY;

AUTOANTIBODIES; AUTOIMMUNITY; BIOMEDICAL RESEARCH; COOPERATIVE BEHAVIOR; DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN-SECRETING CELLS; PANCREAS; PANCREAS TRANSPLANTATION; TISSUE BANKS; TISSUE DONORS;

EID: 84919427535     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-014-0530-0     Document Type: Review

References (69)

1. Pugliese A. The multiple origins of type 1 diabetes. Diabet Med. 2013;30(2):135–46.
2. Herold KC, Vignali DA, Cooke A, Bluestone JA. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol. 2013;13(4):243–56.
3. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol. 2005;23:447–85.
4. Pugliese A, Yang M, Kusmarteva I, Heiple T, Vendrame F, Wasserfall C, et al. The Juvenile Diabetes Research Foundation Network for Pancreatic Organ Donors with Diabetes (nPOD) Program: goals, operational model and emerging findings. Pediatr Diabetes. 2014;15(1):1–9.
5. Campbell-Thompson M, Wasserfall C, Kaddis J, Albanese-O'Neill A, Staeva T, Nierras C, et al. Network for Pancreatic Organ Donors with Diabetes (nPOD): developing a tissue biobank for type 1 diabetes. Diabetes Metab Res Rev. 2012;28(7):608–17.
6. Campbell-Thompson ML, Montgomery EL, Foss RM, Kolheffer KM, Phipps G, Schneider L, et al. Collection protocol for human pancreas. J Vis Exp. 2012;63:e4039.
7. Campbell-Thompson ML, Heiple T, Montgomery E, Zhang L, Schneider L. Staining protocols for human pancreatic islets. J Vis Exp. 2012;63:e4068.
8. Rewers A. Current concepts and controversies in prevention and treatment of diabetic ketoacidosis in children. Curr Diab Rep. 2012;12(5):524–32.
9. Rosenbloom AL. The management of diabetic ketoacidosis in children. Diabetes Ther. 2010;1(2):103–20.
10. Burke GW, III, Vendrame F, Pileggi A, Ciancio G, Reijonen H, and Pugliese A. Recurrence of autoimmunity following pancreas transplantation. CurrDiabRep. 2011.
11. Vendrame F, Pileggi A, Laughlin E, Allende G, Martin-Pagola A, Molano RD, et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes. 2010;59(4):947–57.
12. Sutherland DE, Goetz FC, Sibley RK. Recurrence of disease in pancreas transplants. Diabetes. 1989;38(Supplement 1):85–7.
13. Sibley RK, Sutherland DE. Pancreas transplantation. An immunohistologic and histopathologic examination of 100 grafts. Am J Pathol. 1987;128(1):151–70.
14. Sibley RK, Sutherland DE, Goetz F, Michael AF. Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest. 1985;53(2):132–44.
15. Sutherland DE, Sibley R, Xu XZ, Michael A, Srikanta AM, Taub F, et al. Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes. Trans Assoc Am Physicians. 1984;97:80–7.
16. Diamantopoulos S, Allende G, Martin-Pagola A, Ciancio CR, Messinger S, Burke GW, et al. Recurrence of type 1 diabetes (T1DR) after simultaneous pancreas-kidney (SPK) transplantation is associated with islet cell autoantibody conversion. Acta Diabetol. 2007;44(S1):S13.
17. Kitvarametha YYDS, Allende G, Vendrame F, Snowhite I, Sageshima J, Chen L, Ciancio G, Ruiz P, Reijonen H, Hutton J, Pugliese A, Burke GW. ZnT8 autoantibodies are associated with type 1 diabetes recurrence (T1DR) in simultaneous pancreas-kidney (SPK) transplant recipients. The Review of Diabetic Studies 2011;8(1).
18. Laughlin E, Burke G, Pugliese A, Falk B, Nepom G. Recurrence of autoreactive antigen-specific CD4+ T cells in autoimmune diabetes after pancreas transplantation. Clin Immunol. 2008;128(1):23–30.
19. Martin-Pagola A, Sisino G, Allende G, Dominguez-Bendala J, Gianani R, Reijonen H, et al. Insulin protein and proliferation in ductal cells in the transplanted pancreas of patients with type 1 diabetes and recurrence of autoimmunity. Diabetologia. 2008;51(10):1803–13.
20. Tanaka S, Kobayashi T, Nakanishi K, Okubo M, Murase T, Hashimoto M, et al. Evidence of primary beta-cell destruction by T-cells and beta-cell differentiation from pancreatic ductal cells in diabetes associated with active autoimmune chronic pancreatitis. Diabetes Care. 2001;24(9):1661–7.
21. Campbell-Thompson M, Dixon LR, Wasserfall C, Monroe M, McGuigan JM, Schatz D, et al. Pancreatic adenocarcinoma patients with localised chronic severe pancreatitis show an increased number of single beta-cells, without alterations in fractional insulin area. Diabetologia. 2009;52(2):262–70.
22. Bottino R, Criscimanna A, Casu A, He J, van der Windt DJ, Rudert WA, et al. Recovery of endogenous beta-cell function in nonhuman primates after chemical diabetes induction and islet transplantation. Diabetes. 2009;58(2):442–7.
23. Wang GS, Rosenberg L, Scott FW. Tubular complexes as a source for islet neogenesis in the pancreas of diabetes-prone BB rats. Lab Invest. 2005;85(5):675–88.
24. Liu EH, Digon III BJ, Hirshberg B, Chang R, Wood BJ, Neeman Z, et al. Pancreatic beta cell function persists in many patients with chronic type 1 diabetes, but is not dramatically improved by prolonged immunosuppression and euglycaemia from a beta cell allograft. Diabetologia. 2009;52(7):1369–80.
25. Yip L, Su L, Sheng D, Chang P, Atkinson M, Czesak M, et al. Deaf1 isoforms control the expression of genes encoding peripheral tissue antigens in the pancreatic lymph nodes during type 1 diabetes. NatImmunol. 2009;10(9):1026–33.
26. Spencer J, Peakman M. Post-mortem analysis of islet pathology in type 1 diabetes illuminates the life and death of the beta cell. Clin Exp Immunol. 2009;155(2):125–7.
27. Gianani R, Campbell-Thompson M, Sarkar SA, Wasserfall C, Pugliese A, Solis JM, et al. Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia. 2010;53(4):690–8.
28. Keenan HA, Sun JK, Levine J, Doria A, Aiello LP, Eisenbarth G, et al. Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes. 2010;59(11):2846–53. Provided evidence for the presence of beta cell in the pancreata of T1D patients with long disease duration.
29. Coppieters KT, Wiberg A, Amirian N, Kay TW, von Herrath MG. Persistent glucose transporter expression on pancreatic beta cells from longstanding type 1 diabetic individuals. Diabetes Metab Res Rev. 2011;27(8):746–54.
30. Green-Mitchell SM, Cazares LH, Semmes OJ, Nadler JL, Nyalwidhe JO. On-tissue identification of insulin: in situ reduction coupled with mass spectrometry imaging. Proteomics Clin Appl. 2011;5(7–8):448–53.
31. Coppieters KT, Dotta F, Amirian N, Campbell PD, Kay TW, Atkinson MA, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med. 2012;209(1):51–60. Demonstrated for the first time that autoreactive CD8 T cells are present in the insulitis lesion in the human pancreas, by using tetramers to demonstrate the antigen specificity of the infiltrating lymphocytes.
32. Evanko SP, Potter-Perigo S, Bollyky PL, Nepom GT, Wight TN. Hyaluronan and versican in the control of human T-lymphocyte adhesion and migration. Matrix Biol. 2012;31(2):90–100.
33. Freeby M, Ichise M, Harris PE. Vesicular monoamine transporter, type 2 (vmat2) expression as it compares to insulin and pancreatic polypeptide in the head, body and tail of the human pancreas. Islets. 2012;4(6):393–7.
34. Campbell-Thompson M, Wasserfall C, Montgomery EL, Atkinson MA, Kaddis JS. Pancreas organ weight in individuals with disease-associated autoantibodies at risk for type 1 diabetes. JAMA. 2012;308(22):2337–9.
35. Gregg BE, Moore PC, Demozay D, Hall BA, Li M, Husain A, et al. Formation of a human beta-cell population within pancreatic islets is set early in life. J Clin Endocrinol Metab. 2012;97(9):3197–206.
36. Marhfour I, Lopez XM, Lefkaditis D, Salmon I, Allagnat F, Richardson SJ, et al. Expression of endoplasmic reticulum stress markers in the islets of patients with type 1 diabetes. Diabetologia. 2012;55(9):2417–20.
37. Dai C, Brissova M, Hang Y, Thompson C, Poffenberger G, Shostak A, et al. Islet-enriched gene expression and glucose-induced insulin secretion in human and mouse islets. Diabetologia. 2012;55(3):707–18.
38. Sarkar SA, Lee CE, Victorino F, Nguyen TT, Walters JA, Burrack A, et al. Expression and regulation of chemokines in murine and human type 1 diabetes. Diabetes. 2012;61(2):436–46.
39. Richardson SJ, Leete P, Bone AJ, Foulis AK, Morgan NG. Expression of the enteroviral capsid protein VP1 in the islet cells of patients with type 1 diabetes is associated with induction of protein kinase R and downregulation of Mcl-1. Diabetologia. 2013;56(1):185–93. Reported the presence of viral infection indicators in nPOD pancreata, including donors with long disease duration. This suggests that enteroviral infection of pancreatic beta cells may be chronic and persistent, or there may be multiple hits.
40. Taylor-Fishwick DA, Weaver JR, Grzesik W, Chakrabarti S, Green-Mitchell S, Imai Y, et al. Production and function of IL-12 in islets and beta cells. Diabetologia. 2013;56(1):126–35.
41. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62(7):2595–604.
42. Korpos E, Kadri N, Kappelhoff R, Wegner J, Overall CM, Weber E, et al. The peri-islet basement membrane, a barrier to infiltrating leukocytes in type 1 diabetes in mouse and human. Diabetes. 2013;62(2):531–42. Illustrated mechanisms by which infiltrating leukocytes penetrate islets, mechanisms that could be targeted by therapy.
43. Yip L, Creusot RJ, Pager CT, Sarnow P, Fathman CG. Reduced DEAF1 function during type 1 diabetes inhibits translation in lymph node stromal cells by suppressing Eif4g3. J Mol Cell Biol. 2013;5(2):99–110.
44. Chen J, Feigenbaum L, Awasthi P, Butcher DO, Anver MR, Golubeva YG, et al. Insulin-dependent diabetes induced by pancreatic beta cell expression of IL-15 and IL-15Ralpha. Proc Natl Acad Sci USA. 2013;110:13534–9.
45. Rowe P, Wasserfall C, Croker B, Campbell-Thompson M, Pugliese A, Atkinson M, and Schatz D. Increased Complement Activation in Human Type 1 Diabetes Pancreata. Diabetes Care. 2013.
46. Gardner JM, Metzger TC, McMahon EJ, Au-Yeung BB, Krawisz AK, Lu W, et al. Extrathymic Aire-expressing cells are a distinct bone marrow-derived population that induce functional inactivation of CD4 T cells. Immunity. 2013;13:10. Advanced our knowledge of the origin and mechanism of action of cells that are important in peripheral self-tolerance, including for molecules targeted as autoantigens in T1D.
47. Bogdani M, Johnson PY, Potter-Perigo S, Nagy N, Day AJ, Bollyky PL, and Wight TN. Hyaluronan and hyaluronan binding proteins accumulate in both human type 1 diabetic islets and lymphoid tissues and associate with inflammatory cells in insulitis. Diabetes. 2014. Describes a role for hyaluronan in the inflammatory process that leads to T1D.
48. Gianani R, Putnam A, Still T, Yu L, Miao D, Gill RG, et al. Initial results of screening of nondiabetic organ donors for expression of islet autoantibodies. J Clin Endocrinol Metab. 2006;91(5):1855–61.
49. In't Veld P, Lievens D, De Grijse J, Ling Z, Van der Auwera B, Pipeleers-Marichal M, et al. Screening for insulitis in adult autoantibody-positive organ donors. Diabetes. 2007;56(9):2400–4.
50. Orban T, Sosenko JM, Cuthbertson D, Krischer JP, Skyler JS, Jackson R, et al. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care. 2009;32(12):2269–74.
51. In’t Veld P. Insulitis in human type 1 diabetes: the quest for an elusive lesion. Islets. 2011;3(4):131–8.
52. Krogvold L, Edwin B, Buanes T, Ludvigsson J, Korsgren O, Hyoty H, Frisk G, Hanssen KF, and Dahl-Jorgensen K. Pancreatic biopsy by minimal tail resection in live adult patients at the onset of type 1 diabetes: experiences from the DiViD study. Diabetologia. 2014.
53. Campbell-Thompson ML, Atkinson MA, Butler AE, Chapman NM, Frisk G, Gianani R, et al. The diagnosis of insulitis in human type 1 diabetes. Diabetologia. 2013;56(11):2541–3. Provides consensus guidelines for the diagnosis of human insulitis.
54. Foulis AK, Liddle CN, Farwuharson MA, Richmond JA, Weir RS. The histopathology of the pancreas in type I diabetes (insulin dependent) mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia. 1986;29:267–74.
55. Jaeger C, Brendel MD, Eckhard M, Bretzel RG. Islet autoantibodies as potential markers for disease recurrence in clinical islet transplantation. Exp Clin Endocrinol Diabetes. 2000;108(5):328–33.
56. Pugliese A, Zeller M, Fernandez Jr A, Zalcberg LJ, Bartlett RJ, Ricordi C, et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. NatGenet. 1997;15(3):293–7.
57. Vafiadis P, Bennett ST, Todd JA, Nadeau J, Grabs R, Goodyer CG, et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet. 1997;15(3):289–92.
58. Durinovic-Bello I, Wu RP, Gersuk VH, Sanda S, Shilling HG, Nepom GT. Insulin gene VNTR genotype associates with frequency and phenotype of the autoimmune response to proinsulin. Genes Immun. 2010;11(2):188–93.
59. Durinovic-Bello I, Jelinek E, Schlosser M, Eiermann T, Boehm BO, Karges W, et al. Class III alleles at the insulin VNTR polymorphism are associated with regulatory T-cell responses to proinsulin epitopes in HLA-DR4, DQ8 individuals. Diabetes. 2005;54 Suppl 2:S18–24.
60. Pugliese A, Brown D, Garza D, Murchison D, Zeller M, Redondo M, et al. Self-antigen-presenting cells expressing diabetes-associated autoantigens exist in both thymus and peripheral lymphoid organs. JClinInvest. 2001;107(5):555–64.
61. Gotter J, Brors B, Hergenhahn M, Kyewski B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med. 2004;199(2):155–66.
62. Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science. 2002;298(5597):1395–401.
63. Pugliese A. Insulin: a critical autoantigen and potential therapeutic agent in type 1 diabetes. Expert Rev Clin Immunol. 2006;2(3):419–31.
64. Gardner JM, DeVoss JJ, Friedman RS, Wong DJ, Tan YX, Zhou X, et al. Deletional tolerance mediated by extrathymic Aire-expressing cells. Science. 2008;321(5890):843–7.
65. Klinke DJ. Age-corrected beta cell mass following onset of type 1 diabetes mellitus correlates with plasma C-peptide in humans. PLoS One. 2011;6(11):e26873.
66. Klinke DJ. Extent of beta cell destruction is important but insufficient to predict the onset of type 1 diabetes mellitus. PLoS ONE. 2008;3(1):e1374.
67. Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. Diabetes. 2012;61(8):2066–73. This is an important clinical study that documents changes in C-peptide secretion after diagnosis, showing that significant C-peptide levels persist for at least 2 years after onset in many patients.
68. Oram RA, Jones AG, Besser RE, Knight BA, Shields BM, Brown RJ, et al. The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia. 2014;57(1):187–91. Provides evidence for continuing c-peptide secretion, even if at low levels, in most patients even after many years from onset.
69. Bollyky PL, Bogdani M, Bollyky JB, Hull RL, and Wight TN. The role of hyaluronan and the extracellular matrix in islet inflammation and immune regulation. CurrDiabRep. 2012.